Miller AM - Search Results

1

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. Pavlenko M, et al. Among authors: miller am. Br J Cancer. 2004 Aug 16;91(4):688-94. doi: 10.1038/sj.bjc.6602019. Br J Cancer. 2004. PMID: 15280930 Free PMC article. Clinical Trial.

2

Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.

Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kälkner KM, Pisa P. Ozenci V, et al. Among authors: miller am. Prostate. 2005 Sep 15;65(1):20-6. doi: 10.1002/pros.20229. Prostate. 2005. PMID: 15800933

3

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

Miller AM, Ozenci V, Kiessling R, Pisa P. Miller AM, et al. J Immunother. 2005 Jul-Aug;28(4):389-95. doi: 10.1097/01.cji.0000165353.19171.41. J Immunother. 2005. PMID: 16000958 Clinical Trial.

4

Tumor escape mechanisms in prostate cancer.

Miller AM, Pisa P. Miller AM, et al. Cancer Immunol Immunother. 2007 Jan;56(1):81-7. doi: 10.1007/s00262-005-0110-x. Epub 2005 Dec 16. Cancer Immunol Immunother. 2007. PMID: 16362411 Free PMC article. Review.

5

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.

Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, Pisa P. Miller AM, et al. J Immunol. 2006 Nov 15;177(10):7398-405. doi: 10.4049/jimmunol.177.10.7398. J Immunol. 2006. PMID: 17082659

6

In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients.

Tobiásová Z, Pospísilová D, Miller AM, Minárik I, Sochorová K, Spísek R, Rob L, Bartůnková J. Tobiásová Z, et al. Among authors: miller am. Clin Immunol. 2007 Jan;122(1):18-27. doi: 10.1016/j.clim.2006.09.003. Epub 2006 Oct 23. Clin Immunol. 2007. PMID: 17059893

7

Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials.

Miller AM, Passy AH, Sherry AD, Kouzy R, Abi Jaoude J, Lin TA, Kupferman GS, Beck EJ, Msaouel P, Ludmir EB. Miller AM, et al. JCO Oncol Pract. 2025 Jan 8:OP2400735. doi: 10.1200/OP-24-00735. Online ahead of print. JCO Oncol Pract. 2025. PMID: 39778122

8

Measurement of the ⁷⁰Ge(d,n)⁷¹As cross section from 2.1 MeV to 10 MeV.

Lo YH, Miller AM, Brown G, Peaslee GF, Engle JW, Ellison PA. Lo YH, et al. Among authors: miller am. Appl Radiat Isot. 2024 Dec 30;217:111654. doi: 10.1016/j.apradiso.2024.111654. Online ahead of print. Appl Radiat Isot. 2024. PMID: 39754961

9

Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study.

Kleber TJ, Sherry AD, Arifin AJ, Kupferman GS, Kouzy R, Jaoude JA, Lin TA, Beck EJ, Miller AM, Passy AH, Mccaw ZR, Msaouel P, Ludmir EB. Kleber TJ, et al. Among authors: miller am. J Natl Cancer Inst. 2024 Dec 6:djae318. doi: 10.1093/jnci/djae318. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39657246

10

The retrosplenial cortical role in delayed spatial alternation.

Subramanian DL, Miller AMP, Smith DM. Subramanian DL, et al. Among authors: miller amp. Neurobiol Learn Mem. 2024 Dec;216:108005. doi: 10.1016/j.nlm.2024.108005. Epub 2024 Nov 13. Neurobiol Learn Mem. 2024. PMID: 39542201

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

521 results

Search Page

Filters